Mills Greg B, Ratcovich Hanna, Adams-Hall Jennifer, Beska Benjamin, Kirkup Emma, Raharjo Daniell E, Veerasamy Murugapathy, Wilkinson Chris, Kunadian Vijay
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, 4th Floor William Leech Building, Newcastle upon Tyne NE2 4HH, UK.
University of Copenhagen, Copenhagen, Denmark.
Eur Heart J Open. 2021 Dec 17;2(1):oeab044. doi: 10.1093/ehjopen/oeab044. eCollection 2022 Jan.
Globally, ischaemic heart disease is the leading cause of death, with a higher mortality burden amongst older adults. Although advancing age is associated with a higher risk of adverse outcomes following acute coronary syndrome (ACS), older patients are less likely to receive evidence-based medications and coronary angiography. Guideline recommendations for managing ACS are often based on studies that exclude older patients, and more contemporary trials have been underpowered and produced inconsistent findings. There is also limited evidence for how frailty and comorbidity should influence management decisions. This review focuses on the current evidence base for the medical and percutaneous management of ACS in older patients and highlights the distinct need to enrol older patients with ACS into well-powered, large-scale randomized trials.
在全球范围内,缺血性心脏病是主要的死亡原因,在老年人中造成的死亡负担更高。尽管年龄增长与急性冠状动脉综合征(ACS)后不良结局风险增加相关,但老年患者接受循证药物治疗和冠状动脉造影的可能性较小。管理ACS的指南建议通常基于排除老年患者的研究,而更多当代试验的样本量不足且结果不一致。关于衰弱和合并症应如何影响管理决策的证据也很有限。本综述聚焦于老年ACS患者药物治疗和经皮治疗的现有证据基础,并强调了将老年ACS患者纳入样本量充足的大规模随机试验的迫切需求。